Thursday, 16 January 2014

Ranbaxy likely to tie-up with MNC to source Diovan APIs .

Diovan was the drug which was off-patented in September 2012 and Ranbaxy has a first-to-file (FTF) status over it. This means they will get six months of marketing exclusivity in the market. 

Read more at: http://www.moneycontrol.com/news/cnbc-tv18-comments/ranbaxy-likely-to-tie-upmnc-to-source-diovan-apis_1025660.html?utm_source=ref_article

No comments:

Post a Comment

Blogroll